Legend Biotech(US:LEGN)2025-11-12 13:00CARVYKTI® Performance and Market Position - CARVYKTI® achieved net trade sales of $524 million in Q3 2025, representing an 84% year-over-year (YoY) growth[23] - Over 9,000 clinical and commercial patients have been treated with CARVYKTI® to date[23] - CARVYKTI® label was updated by the FDA to include Overall Survival (OS) analysis from the Phase 3 CARTITUDE-4 study[23] - U S QoQ growth of 11% primarily driven by continued strong demand with 60% utilization in earlier line settings[51] - OUS QoQ growth of 58% primarily driven by launch uptake in 14 markets worldwide[51] Clinical Advancements and Pipeline - CARTITUDE-4 study showed approximately a 70% reduction in the risk of progression or death in patients who received cilta-cel[27] - The CARTITUDE-4 study also demonstrated a 45% reduction in the risk of death in patients receiving cilta-cel versus standard of care (SOC)[27] - The company has 10 pipeline programs, including hematologic malignancies, solid tumors, and autoimmune diseases[43] - Greatest benefit in 1 prior line of therapy, reducing the risk of progression or death versus SOC with a hazard ratio (HR) of 0 35[36] Financial Performance and Outlook - The company has a cash position of approximately $1 billion as of September 30, 2025[43, 75] - Operating margin improved from -142% in Q2 2023 to -16% in Q3 2025[66] - Adjusted net loss improved from $42 million in Q3 2024 to $19 million in Q3 2025[68]